GlaxoSmithKline warns on profits as China bribes crisis bites
Thirty staff have been sacked in China amid allegations that doctors were bribed to use GSK’s products
Thursday 24 July 2014
GlaxoSmithKline slashed its growth forecasts and stopped a billion-pound plus share buyback yesterday as its chief executive, Sir Andrew Witty, said he remained “concerned” about allegations that it bribed doctors in China to prescribe its drugs.
A strong pound and falling sales of its key lung drugs in the US also hit the pharmaceutical giant’s results.
GSK shares dived on the news, falling as much as 6.9 per cent before ending down 73.5p, or nearly 5 per cent, at 1,481.5p – their lowest point since the China scandal broke just over a year ago.
Chinese officials have charged a private investigator, Peter Humphrey, who worked for GSK, and his wife, with illegally trading personal information, while sex tapes have come to light of its former China head Mark Reilly and his Chinese girlfriend.
Under-pressure Sir Andrew yesterday revealed another set of quarterly results with little sign of the promised recovery in sales’ growth. Revenues for the latest three months dropped 16 per cent to £5.56bn while core operating profits were down 25 per cent at £1.4bn.
Sales of GSK’s drugs and vaccines in the US fell by 10 per cent, mostly due to increased competition from generic drugs. Sales of its blockbuster asthma treatment Advair fell 12 per cent in the second quarter, having fallen by 15 per cent in the first.
The ongoing investigations in China also hit sales badly there, with revenues down by 20 per cent. Sir Andrew said that GSK took the allegations seriously and investigated every claim of wrongdoing, taking action if they had substance. “We have zero tolerance for unethical behaviour,” he said. “The vast majority of our employees operate ethically and we are continuing to cooperate with the Chinese investigations.”
Thirty staff have been sacked in China amid allegations that doctors were bribed to use GSK’s products.
Sir Andrew said GSK remained “committed to China” and expected sales growth there to “begin to recover” in the current third quarter. He also highlighted global new product launches but admitted that they were costing more to get to market and to sell.
GSK said it now expects no growth in earnings per share in 2014 against its previous indications of 4 to 8 per cent growth. It added that it would not now give any guidance on earnings prospects beyond the current year.
Mark Clark, an analyst at Deutsche Bank, said the City would have to cut earnings forecasts for the group by more than 5 per cent, and GSK’s poor performance could put its dividend policy under pressure.
Sir Andrew added: “Our good progress on newly launched products is being offset by pricing and contracting pressure in the US.
“As we highlighted last quarter, this has resulted in a ‘step change’ reduction in Advair market share and pricing, and it is now clear that these pressures are likely to continue.”
- 1 Tourist films plane's descent just metres above packed Caribbean beach
- 2 Kate Moss: Previously unpublished nude photo revealed by Mert and Marcus
- 3 Indian woman creates 'Marriage CV' after parents put her on dating site: 'Definitely not marriage material. Won’t grow long hair, ever'
- 4 World Book Day: Boy 'excluded' from school after dressing up as Fifty Shades' Christian Grey
- 5 Bad Jews poster 'censored' on London Tube
Tourist films plane's descent just metres above packed Caribbean beach
Indian woman creates 'Marriage CV' after parents put her on dating site: 'Definitely not marriage material. Won’t grow long hair, ever'
Becky Watts: Four appear in court charged with hiding body parts after teenager's death
Isis 'bulldozes' Nimrud: UNESCO condemns destruction of ancient Assyrian site as a 'war crime'
Professor Brian Cox brands astrology-believing Tory MP David Tredinnick an 'outlier on the spectrum of reason'
Nearly 100,000 of Britain's poorest children go hungry after parents' benefits are cut
Durham Free School: 'Creationism taught at' free school facing closure
End of the licence fee: BBC to back radical overhaul of how it is funded
Elif Shafak: Turkish author warns against rise of British nationalism
Most people think legal tax avoidance is just as wrong as illegal tax evasion, poll suggests
Nigel Farage promises Ukip will not 'stigmatise' would-be migrants – and says he wants 'everyone to speak the same language'
iJobs Money & Business
£13000 per annum: Recruitment Genius: This is an exciting opportunity to join ...
£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...
£12 - £15 Hourly Rate: Jemma Gent: In this role you will report to the Head of...
£8 per hour: Recruitment Genius: This Pension Specialist was established early...